Video Experimental Relacionado
Updated: May 6, 2026
08:44
Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
8.4K
Maximizar el sistema de péptido natriurético en la insuficiencia cardíaca experimental: péptido natriurético
Horng H Chen1, John G Lainchbury, Gail J Harty
1Cardiorenal Research Laboratory, Division of Cardiovascular Diseases and Department of Physiology, Mayo Clinic and Foundation, Rochester, Minn 55905, USA. chen.horng@mayo.edu
Circulation
|February 28, 2002
Resumen
La administración de un inhibidor agudo de la vasopeptidasa (VPI) potencia los efectos del péptido natriurético cerebral (BNP) en la insuficiencia cardíaca congestiva experimental (CHF). La combinación de VPI con BNP ofrece una nueva estrategia terapéutica para mejorar la función cardiorrenal en pacientes con insuficiencia cardíaca congestiva.
Área de la Ciencia:
- Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular
- Farmacología Farmacología.
- Nefrología Nefrología.
Sus antecedentes:
- La insuficiencia cardíaca congestiva (ICF) se caracteriza por el aumento de los péptidos natriuréticos cardíacos (NP) con propiedades cardiorenales beneficiosas.
- La administración crónica subcutánea (SQ) de péptido natriurético cerebral (BNP) mejora la función cardiorrenal en el CHF experimental.
- Los inhibidores de la vasopeptidasa (IPV) inhiben simultáneamente la endopeptidasa neutra (EPN) y la ECA.
Objetivo del estudio:
- Investigar si la administración aguda de VPI potencia las acciones cardiorenales de SQ BNP en pacientes experimentales con CHF.
- Evaluar los efectos combinados de VPI y BNP en las respuestas cardiorenal y humoral.
Principales métodos:
- Se estudiaron perros anestesiados con insuficiencia cardíaca congestiva inducida por el ritmo ventricular.
- Los grupos recibieron solo IPV agudo, dosis baja de SQ BNP solo, dosis alta de SQ BNP solo, o IPV más dosis baja de SQ BNP.
- Se midieron los parámetros cardiorenal y humoral.
Principales resultados:
- El IPV más la dosis baja de SQ BNP aumentaron significativamente los niveles plasmáticos de BNP en comparación con el IPV o la dosis baja de BNP solo.
- La administración combinada de VPI y BNP dio como resultado la mayor excreción urinaria de BNP y sodio.
- La terapia combinada condujo al mayor aumento en la tasa de filtración glomerular, el rendimiento cardíaco y la reducción en las presiones de llenado cardíaco.
Conclusiones:
- La administración aguda de VPI potencia los efectos cardiorenales de SQ BNP en el CHF experimental.
- La combinación de la terapia proteica con el BNP y la inhibición de vasopéptidos presenta una nueva estrategia para el tratamiento de la insuficiencia cardíaca congestiva.
- Este enfoque maximiza los beneficios terapéuticos del sistema de péptido natriurético en el manejo de CHF.
Videos de Conceptos Relacionados
01:23Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
01:22Heart Failure Drugs: Diuretics
1.8K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:22Heart Failure Drugs: β-Blockers
2.9K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.9K
01:29Heart Failure II: Pathophysiology
2.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.1K
01:30Heart Failure V: Medical Management
641
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
641